463 related articles for article (PubMed ID: 15000587)
1. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
Aceti A; Carosi G
Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
4. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
Montroni M; Monforte AD
Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
[TBL] [Abstract][Full Text] [Related]
5. Genotypic resistance tests for the management of the patient failing highly active antiretroviral therapy: the resistance pattern in different biological compartments.
Liuzzi G
Scand J Infect Dis Suppl; 2003; 106():90-3. PubMed ID: 15000595
[TBL] [Abstract][Full Text] [Related]
6. Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy.
Suter F; Ghinelli F
Scand J Infect Dis Suppl; 2003; 106():82-5. PubMed ID: 15000592
[TBL] [Abstract][Full Text] [Related]
7. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
Bassetti D; Cargnel A
Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
[TBL] [Abstract][Full Text] [Related]
9. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
Visco-Comandini U; Balotta C
Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
[TBL] [Abstract][Full Text] [Related]
11. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
[TBL] [Abstract][Full Text] [Related]
12. Genotypic resistance tests for the management of patients with viro-immunological discordant response to highly active antiretroviral therapy.
Moroni M
Scand J Infect Dis Suppl; 2003; 106():85-7. PubMed ID: 15000593
[TBL] [Abstract][Full Text] [Related]
13. [Drug resistance in antiretroviral therapy of HIV infection].
Oette M; Häussinger D
Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
[TBL] [Abstract][Full Text] [Related]
15. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
[TBL] [Abstract][Full Text] [Related]
16. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
17. How does expert advice impact genotypic resistance testing in clinical practice?
Badri SM; Adeyemi OM; Max BE; Zagorski BM; Barker DE
Clin Infect Dis; 2003 Sep; 37(5):708-13. PubMed ID: 12942405
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Hirsch MS; Brun-Vézinet F; Clotet B; Conway B; Kuritzkes DR; D'Aquila RT; Demeter LM; Hammer SM; Johnson VA; Loveday C; Mellors JW; Jacobsen DM; Richman DD
Clin Infect Dis; 2003 Jul; 37(1):113-28. PubMed ID: 12830416
[TBL] [Abstract][Full Text] [Related]
19. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
20. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M; Prosperi M; Vicenti I; Di Giambenedetto S; Callegaro A; Bruzzone B; Baldanti F; Gonnelli A; Boeri E; Paolini E; Rusconi S; Giacometti A; Maggiolo F; Menzo S; De Luca A;
J Antimicrob Chemother; 2009 Sep; 64(3):616-24. PubMed ID: 19620134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]